Cancer cells also present the HLA class II antigen in the absence of the CD80/CD86 universe-stimulating molecules, this frequent representation of cancer cell antigens drives T-cell anergy thus, imparting cancer tolerance (Byrne and Halliday, 2003). This evidence concerns the gene CD86 and cancer.